venBio Select Advisor LLC purchased a new position in shares of Kodiak Sciences Inc. (NYSE:KOD) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 902,200 shares of the company’s stock, valued at approximately $6,406,000. Kodiak Sciences makes up 0.4% of venBio Select Advisor LLC’s portfolio, making the stock its 27th biggest holding. venBio Select Advisor LLC owned about 2.45% of Kodiak Sciences at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Jennison Associates LLC acquired a new position in Kodiak Sciences in the fourth quarter valued at $5,662,000. BlackRock Inc. acquired a new position in Kodiak Sciences in the fourth quarter valued at $3,139,000. Northern Trust Corp acquired a new position in Kodiak Sciences in the fourth quarter valued at $487,000. Geode Capital Management LLC acquired a new position in Kodiak Sciences in the fourth quarter valued at $458,000. Finally, Bank of New York Mellon Corp acquired a new position in Kodiak Sciences in the fourth quarter valued at $94,000.
Shares of Kodiak Sciences stock traded down $0.11 on Friday, reaching $6.89. 605 shares of the stock were exchanged, compared to its average volume of 62,282. Kodiak Sciences Inc. has a 1-year low of $5.65 and a 1-year high of $11.10.
KOD has been the topic of a number of recent research reports. Chardan Capital initiated coverage on shares of Kodiak Sciences in a research note on Wednesday, February 20th. They issued a “buy” rating and a $22.50 price objective on the stock. Zacks Investment Research lowered shares of Kodiak Sciences from a “hold” rating to a “sell” rating in a research note on Thursday, January 17th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Kodiak Sciences has a consensus rating of “Buy” and a consensus price target of $19.13.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Fairfield Current and is owned by of Fairfield Current. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/03/15/venbio-select-advisor-llc-purchases-new-position-in-kodiak-sciences-inc-kod.html.
Kodiak Sciences Company Profile
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company’s lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.
Further Reading: What is Compound Interest?
Want to see what other hedge funds are holding KOD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kodiak Sciences Inc. (NYSE:KOD).
Receive News & Ratings for Kodiak Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kodiak Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.